VIP (Vasoactive Intestinal Peptide): Clinical Overview

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide first isolated from intestine but distributed widely through the nervous system, lungs, gut and immune tissue. Its synthetic form is aviptadil. It has an extensive and legitimate biology, a repeatedly disappointing therapeutic record, and a pattern of use in some functional medicine settings that is not supported by evidence.

This guide situates VIP within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What VIP does

VIP acts at two G-protein coupled receptors, VPAC1 and VPAC2, which are distributed across the lungs, gut, immune cells, vasculature and central nervous system. That distribution explains the breadth of its effects.

Its documented actions include vasodilation, bronchodilation, stimulation of intestinal secretion, relaxation of smooth muscle, and a range of immunomodulatory effects that are generally anti-inflammatory — shifting cytokine production away from pro-inflammatory patterns and supporting regulatory T cell function.

It also has an established role in pathology: VIPomas, rare pancreatic tumors secreting VIP, cause profuse watery diarrhea, hypokalemia and achlorhydria. That syndrome demonstrates unambiguously that VIP has powerful systemic effects at sufficient concentration.

Its plasma half-life is very short — on the order of a minute or two — which is the central constraint on using it as a drug.

What the trials found

Aviptadil has been investigated across several indications over decades, including pulmonary arterial hypertension, sarcoidosis and acute lung injury, on the reasonable basis that a pulmonary vasodilator with anti-inflammatory activity might help in those settings.

It received considerable attention during the COVID-19 pandemic as a candidate for acute respiratory distress syndrome, given VIP's concentration in the lung and its protective effects on alveolar type II cells in preclinical work. Clinical trial results did not establish the benefit that early enthusiasm anticipated, and it did not achieve approval for that use.

A combination of VIP with phentolamine has been approved in some countries outside the United States for erectile dysfunction, delivered by intracavernosal injection — a setting where local delivery circumvents the half-life problem entirely.

The overall pattern is familiar in this field: strong mechanistic rationale, encouraging preclinical work, and clinical trials that did not confirm the expected benefit.

The functional medicine question

VIP is used in some functional and environmental medicine practices, typically as an intranasal preparation, within protocols addressing conditions attributed to mold or biotoxin exposure — frequently described as chronic inflammatory response syndrome.

This warrants a direct assessment. The proposed rationale rests on VIP's anti-inflammatory and neuroregulatory properties, which are real. What is absent is controlled clinical trial evidence demonstrating that intranasal VIP improves outcomes in these conditions. The supporting material consists largely of case series and protocol descriptions from practitioners who developed the approach, without independent randomized evaluation.

The underlying diagnostic framework is itself contested within mainstream medicine, which compounds the difficulty of assessing a treatment for it.

This is not an argument that patients presenting with these symptoms are not unwell. It is that a peptide with genuine biology and a poor clinical trial record, used off-label within a contested diagnostic framework and without controlled evidence, should be described accurately to patients rather than presented as established therapy.

Regulatory status

Aviptadil is not FDA-approved in the United States. VIP preparations obtained through compounding pharmacies for intranasal or other use sit in a position that should be verified directly rather than assumed, and this category's status has changed repeatedly.

Given the very short half-life, formulation and delivery are not incidental details — they determine whether meaningful exposure occurs at all. Our peptide formulary tracks current status for every agent.